X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TEVA PHARMA (Israel) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   TEVA PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
TEVA PHARMA
Dec-13
DR. REDDYS LAB/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3972,666-   
Low Rs2,5602,316-   
Sales per share (Unadj.) Rs856.51,529.8-  
Earnings per share (Unadj.) Rs78.095.6-  
Cash flow per share (Unadj.) Rs139.9219.2-  
Dividends per share (Unadj.) Rs20.0083.66-  
Dividend yield (eoy) %0.73.4 20.0%  
Book value per share (Unadj.) Rs739.81,699.3-  
Shares outstanding (eoy) m165.74848.00-   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.51.6 213.6%   
Avg P/E ratio x38.226.1 146.6%  
P/CF ratio (eoy) x21.311.4 187.4%  
Price / Book Value ratio x4.01.5 274.7%  
Dividend payout %25.787.5 29.3%   
Avg Mkt Cap Rs m493,6322,111,978 23.4%   
No. of employees `00022.744.9 50.5%   
Total wages/salary Rs m31,0680-   
Avg. sales/employee Rs Th6,259.028,863.1 21.7%   
Avg. wages/employee Rs Th1,369.80-   
Avg. net profit/employee Rs Th569.71,803.1 31.6%   
INCOME DATA
Net Sales Rs m141,9611,297,252 10.9%  
Other income Rs m1,7150-   
Total revenues Rs m143,6761,297,252 11.1%   
Gross profit Rs m24,722355,253 7.0%  
Depreciation Rs m10,266104,858 9.8%   
Interest Rs m63425,480 2.5%   
Profit before tax Rs m15,537224,915 6.9%   
Minority Interest Rs m01,022 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0-147,644 0.0%   
Tax Rs m2,965-2,746 -108.0%   
Profit after tax Rs m12,92181,038 15.9%  
Gross profit margin %17.427.4 63.6%  
Effective tax rate %19.1-1.2 -1,563.1%   
Net profit margin %9.16.2 145.7%  
BALANCE SHEET DATA
Current assets Rs m96,837876,159 11.1%   
Current liabilities Rs m84,199764,085 11.0%   
Net working cap to sales %8.98.6 103.0%  
Current ratio x1.21.1 100.3%  
Inventory Days Days7391 80.8%  
Debtors Days Days9896 101.8%  
Net fixed assets Rs m102,552423,711 24.2%   
Share capital Rs m8293,193 26.0%   
"Free" reserves Rs m121,7920-   
Net worth Rs m122,6211,441,001 8.5%   
Long term debt Rs m5,449663,314 0.8%   
Total assets Rs m218,1652,964,637 7.4%  
Interest coverage x25.59.8 259.6%   
Debt to equity ratio x00.5 9.7%  
Sales to assets ratio x0.70.4 148.7%   
Return on assets %6.23.6 172.9%  
Return on equity %10.55.6 187.4%  
Return on capital %12.94.9 261.6%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Net fx Rs m55,3150-   
CASH FLOW
From Operations Rs m21,444206,715 10.4%  
From Investments Rs m-18,404-73,247 25.1%  
From Financial Activity Rs m-3,692-247,968 1.5%  
Net Cashflow Rs m-1,144-114,501 1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.86 Rs / USD

Compare DR. REDDYS LAB With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare DR. REDDYS LAB With: AJANTA PHARMA  SUN PHARMA  NOVARTIS  UNICHEM LAB  ALEMBIC PHARMA  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views On News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jan 18, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - FDC LTD. COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS